论文部分内容阅读
目的评价胸腔置管引流联合胸腔内灌注康莱特治疗晚期肺癌恶性胸腔积液的临床疗效和不良反应。方法 60例晚期肺癌恶性胸腔积液患者,随机分成治疗组和对照组,各30例。治疗组胸腔内灌注康莱特治疗,对照组胸腔内灌注博莱霉素治疗。比较两组临床疗效。结果治疗组胸腔积液乳酸脱氢酶水平(LDH)治疗前后差值为(83.900±3.078)U/L,明显高于对照组的(45.170±2.878)U/L(P<0.05);两组胸腔积液控制有效率、改良呼吸困难评分(mMRC评分)、生活质量评分(Karnofsky评分)比较差异均无统计学意义(P>0.05);两组胸痛不良反应比较,差异有统计学意义(P<0.05)。结论胸腔置管引流并胸腔内灌注康莱特治疗晚期肺癌恶性胸腔积液安全、有效、不良反应较少。
Objective To evaluate the clinical efficacy and adverse reactions of pleural catheter drainage combined with pleural perfusion of Kanglaite in the treatment of advanced lung cancer with malignant pleural effusion. Methods Sixty patients with advanced lung cancer with malignant pleural effusion were randomly divided into treatment group and control group, with 30 cases in each. The treatment group was infused with KLT and the control group was treated with intrapleural injection of bleomycin. The clinical efficacy of the two groups were compared. Results The difference between before and after LDH treatment in treatment group was (83.900 ± 3.078) U / L, which was significantly higher than that in control group (45.170 ± 2.878) U / L (P <0.05) Pleural effusion control efficiency, modified dyspnea score (mMRC score), quality of life score (Karnofsky score) showed no significant difference (P> 0.05); two groups of adverse reactions chest pain, the difference was statistically significant (P <0.05). Conclusions Pleural catheter drainage and intrapleural infusion of Kanglaite in the treatment of advanced lung cancer with malignant pleural effusion is safe and effective with few adverse reactions.